Since its establishment in 1995, the Agency has harmonised and improved the evaluation of medicines, stimulated innovation, improved safety monitoring and risk management, fostered transparency and dialogue, built relationships with international partners and helped to make medicines accessible to those who need them. To achieve this, EMA has worked closely with the national authorities in EU Member States, the European Commission, international partners and civil society.
